Direct Meds review

No single-month commitment is established. The injection offers reviewed in October 2026 display a 90-day shipment, while the subscription terms describe charges every 30 days. Delivery duration and payment timing are different: receiving medication together does not establish that one payment settles the order. The number of payments and any remaining balance after cancellation are not established by the reviewed public terms. Obtain those details for the selected plan before relying on a monthly headline or canceling after delivery.

The October 2026 public offers list injectable tirzepatide at $399/month and injectable semaglutide at $297/month. The separate sublingual offers list $299/month for tirzepatide and $249/month for semaglutide. These are advertised product prices, rather than a verified personal invoice. The injection display pairs a 90-day shipment with monthly billing. A lower sublingual price does not establish dose equivalence, equivalent absorption or equivalent clinical results. Confirm the prescribed route, quantity, payment schedule and total obligation for the actual offer.

Switch off auto-refill in the portal at least 48 hours before the next processing date. The terms separately describe notice 5–7 days before a subscription charge; receiving that notice is not itself a cancellation. For a new prescription order, cancellation is only an attempt within the first 24 hours and before provider-network receipt. Once that boundary passes, ordinary order cancellation is generally unavailable. Confirm both the future refill status and any pending order, because stopping future auto-refills does not establish that an existing shipment or payment obligation has been canceled.

The terms list exceptions for wrong, damaged, unsafe, unshipped or clinician-denied medication. Report a delivery problem within 48 hours and retain the order and delivery details for review. A returned prescription carries a $35 disposal fee under the terms. These limited remedies do not establish a general right to ordinary medication returns or a guaranteed refund for every complaint. Ask which exception applies and what handling is required; a safety concern should be addressed with the dispensing pharmacy or clinician rather than treated as proof that the medication is usable.

The seller’s product FAQ routes most covered states and Washington, DC, to CraftedRx in Warrenton, Missouri, and Alabama, California, Connecticut, North Carolina, South Carolina and Washington to ChemistryRx in Folcroft, Pennsylvania. It excludes Mississippi and Louisiana and includes Washington, DC, in the routing list. Its 503B sourcing statement remains independently unverified for each named facility. A named partner and a state-routing table do not prove an individual prescription assignment: the terms allow the pharmacy to vary with location and availability. Confirm the selected product’s eligibility and actual dispenser.

The product FAQ describes doctor review, medication, supplies and shipping as bundled. Injection copy says small insulin-sized needles are supplied, but the full kit count is not itemized. The FAQ describes clinician dose review before another prescription when medication runs out; that is not a published quota of scheduled follow-up visits. Care-team access also does not establish dietitian sessions or a fixed coaching schedule. No public lab gate is documented, but that does not mean testing is unnecessary or funded. Ask what assessment and monitoring the clinician requires and whether any ordered tests cost extra.